Homology Medicines Inc.

2.03-0.2200-9.78%Vol 4.37M1Y Perf -69.22%
Jun 24th, 2022 16:00 DELAYED
BID1.90 ASK2.37
Open2.25 Previous Close2.25
Pre-Market- After-Market2.08
 - -  0.05 2.46%
Target Price
13.83 
Analyst Rating
Moderate Buy 2.00
Potential %
581.28 
Finscreener Ranking
★★★★★     59.99
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★     56.98
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★+     65.40
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.61 
Earnings Rating
Sell
Market Cap116.49M 
Earnings Date
11th Aug 2022
Alpha-0.03 Standard Deviation0.17
Beta-0.21 

Today's Price Range

2.022.39

52W Range

1.308.90

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
13.41%
1 Month
41.96%
3 Months
-33.66%
6 Months
-50.97%
1 Year
-69.22%
3 Years
-89.24%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FIXX2.03-0.2200-9.78
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
ValuationValueIndustryS&P 500US Markets
-22.40
0.39
18.79
57.40
6.20
-1.94
0.39
4.64
-129 423 000.00
Forward PE-0.92
PEG-1.17
Financial StrengthValueIndustryS&P 500US Markets
12.30
12.60
0.08
0.09
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-2 422.40
-2 301.30
-
-47.29
RevenueValueIndustryS&P 500US Markets
5.47M
0.10
91.32
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.25-0.2020.00
Q04 2021-0.58-0.59-1.72
Q03 2021-0.60-0.5410.00
Q02 2021-0.58-0.546.90
Q01 2021-0.65-0.0296.92
Q04 2020-0.65-0.624.62
Q03 2020-0.81-0.6223.46
Q02 2020-0.81-0.783.70
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.57-7.55Negative
9/2022 QR-0.57-1.79Negative
12/2022 FY-1.863.13Positive
12/2023 FY-1.9311.06Positive
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.57
Estimates Count5
EPS Growth Next 5 Years %19.10
Volume Overview
Volume4.37M
Shares Outstanding57.39K
Shares Float46.83M
Trades Count6.06K
Dollar Volume8.95M
Avg. Volume453.84K
Avg. Weekly Volume484.42K
Avg. Monthly Volume443.88K
Avg. Quarterly Volume433.22K

Homology Medicines Inc. (NASDAQ: FIXX) stock closed at 2.03 per share at the end of the most recent trading day (a -9.78% change compared to the prior day closing price) with a volume of 4.37M shares and market capitalization of 116.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 206 people. Homology Medicines Inc. CEO is Arthur O. Tzianabos.

The one-year performance of Homology Medicines Inc. stock is -69.22%, while year-to-date (YTD) performance is -44.23%. FIXX stock has a five-year performance of %. Its 52-week range is between 1.3 and 8.9, which gives FIXX stock a 52-week price range ratio of 9.61%

Homology Medicines Inc. currently has a PE ratio of -22.40, a price-to-book (PB) ratio of 0.39, a price-to-sale (PS) ratio of 18.79, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -0.95%, a ROC of -1.09% and a ROE of -1.11%. The company’s profit margin is -47.29%, its EBITDA margin is -2 301.30%, and its revenue ttm is $5.47 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Homology Medicines Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Homology Medicines Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Homology Medicines Inc. is Moderate Buy (2), with a target price of $13.83, which is +581.28% compared to the current price. The earnings rating for Homology Medicines Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Homology Medicines Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Homology Medicines Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.27, ATR14 : 0.22, CCI20 : 84.89, Chaikin Money Flow : -0.30, MACD : 0.07, Money Flow Index : 37.37, ROC : -8.56, RSI : 54.55, STOCH (14,3) : 48.65, STOCH RSI : 0.44, UO : 51.93, Williams %R : -51.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Homology Medicines Inc. in the last 12-months were: Albert Seymour (Option Excercise at a value of $0), Albert Seymour (Sold 1 661 shares of value $6 279 ), Arthur O. Tzianabos (Option Excercise at a value of $0), Arthur O. Tzianabos (Sold 5 354 shares of value $20 239 ), Gabriel Cohn (Option Excercise at a value of $0), Gabriel Cohn (Sold 1 661 shares of value $6 279 ), Timothy P. Kelly (Option Excercise at a value of $0), Timothy P. Kelly (Sold 2 974 shares of value $11 877 ), W. Bradford Smith (Option Excercise at a value of $0), W. Bradford Smith (Sold 2 182 shares of value $8 248 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (50.00 %)
4 (50.00 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (50.00 %)
4 (50.00 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
1.86

Homology Medicines Inc.

Homology Medicines Inc is an US based is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

CEO: Arthur O. Tzianabos

Telephone: +1 781 301-7277

Address: One Patriots Park, Bedford 01730, MA, US

Number of employees: 206

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

68%32%

Bearish Bullish

60%40%

TipRanks News for FIXX

News

Stocktwits